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Introduction
Magnetic resonance imaging (MRI) plays a pivotal 
role in the diagnosis and monitoring of multiple 
sclerosis (MS).1,2 After clinically isolated syndrome 
(CIS), which is commonly the first manifestation of 
MS, 56%–82% of patients with brain MRI abnor-
malities will develop clinically definite MS within 
the next 20 years.3,4 For patients with a normal brain 
MRI, this is much lower, approximately 20%.3,4  
An early accurate diagnosis is highly relevant in 
clinical decision making, such as initiation of dis-
ease-modifying therapy in early stage of the dis-
ease. Moreover, precise lesion detection is important 
in identifying patients with an increased risk of 
long-term disability, mainly patients with a high 
lesion load, gadolinium enhancing lesions and 
infratentorial lesions.5–7 In addition, adequate moni-
toring of CIS and MS patients requires an accurate 
detection of new lesions.1,2
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Abstract
Background: Compared to 1.5 T, 3 T magnetic resonance imaging (MRI) increases signal-to-noise ratio 
leading to improved image quality. However, its clinical relevance in clinically isolated syndrome sug-
gestive of multiple sclerosis remains uncertain.
Objectives: The purpose of this study was to investigate how 3 T MRI affects the agreement between 
raters on lesion detection and diagnosis.
Methods: We selected 30 patients and 10 healthy controls from our ongoing prospective multicentre 
cohort. All subjects received baseline 1.5 and 3 T brain and spinal cord MRI. Patients also received 
follow-up brain MRI at 3–6 months. Four experienced neuroradiologists and four less-experienced rat-
ers scored the number of lesions per anatomical region and determined dissemination in space and time 
(McDonald 2010).
Results: In controls, the mean number of lesions per rater was 0.16 at 1.5 T and 0.38 at 3 T (p = 0.005). 
For patients, this was 4.18 and 4.40, respectively (p = 0.657). Inter-rater agreement on involvement per 
anatomical region and dissemination in space and time was moderate to good for both field strengths. 
3 T slightly improved agreement between experienced raters, but slightly decreased agreement between 
less-experienced raters.
Conclusion: Overall, the interobserver agreement was moderate to good. 3 T appears to improve the read-
ing for experienced readers, underlining the benefit of additional training.
Keywords: Multiple sclerosis, clinically isolated syndrome, magnetic resonance imaging, interobserver 
variation, multicentre study
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The current McDonald 2010 diagnostic criteria for MS 
do not define MRI acquisition parameters such as mag-
netic field strength, spatial resolution and the selection 
of pulse sequences.8 Mainly due to the improved sig-
nal-to noise ratio leading to an improvement of image 
quality, brain imaging at higher magnetic field strengths 
offers new possibilities with respect to the diagnosis 
and follow-up of neuroinflammatory disease.9–11 
Current expert panel guidelines recommend 3 T brain 
imaging,1,2 as the improved signal-to-noise ratio results 
in an increased lesion detection in anatomical regions 
relevant for dissemination in space (DIS), especially in 
the (juxta)cortical, periventricular and infratentorial 
region.12,13 However, the clinical relevance of high 
field strength MRI is uncertain. In particular, the ques-
tion remains, whether the use of 3 T leads to an earlier 
diagnosis of MS. A previous prospective single-centre 
and single-vendor study with 40 CIS patients demon-
strated an increased lesion detection on brain scans, but 
as such this did not lead to an earlier diagnosis of MS 
according to the McDonald 2005 and Swanton crite-
ria.14,15 Moreover, when retrospectively applying the 
2010 revised McDonald criteria to this dataset, this out-
come did not change.16
The purpose of this prospective multicentre, multi-
vendor and multi-rater study in patients presenting 
with a CIS was to evaluate the effect of 3 T MRI on 
interobserver agreement on lesions detection and sub-
sequently fulfilment of the criteria for DIS and dis-
semination in time (DIT). Additionally, we evaluated 
the effect of the raters’ experience on the interobserver 
agreement for both the lesion detection and the 
McDonald diagnostic criteria.
Materials and methods
This study is part of a MAGNIMS (Magnetic 
Resonance Imaging in MS, http://www.magnims.eu) 
prospective multicentre, multi-vendor project con-
ducted at the following MS Centres: VU University 
Medical Center Amsterdam, University Hospital of 
Basel, St. Josef Hospital Bochum, UCL Institute of 
Neurology London, Hospital Clínico San Carlos 
Madrid and Sapienza University of Rome.
At each centre, the study design was approved by the 
local institutional review board. Written informed 
consent was obtained from all participants.
For the CIS patients, two visits were used for this analy-
sis: the baseline visit and the first follow-up 3 to 6 months 
later (Figure 1). As at this interval, no change on MRI 
scans is to be expected for healthy controls; only base-
line visits were scheduled for the control group.
Recruitment of subjects
Patients with CIS suggestive of MS, as defined by 
the International Panel on MS diagnosis,8 were 
recruited from the outpatient clinics of the six par-
ticipating centres between July 2013 and September 
2015. Patients were recruited within 6 months after 
the first clinical episode suggestive of demyelina-
tion. All subjects were aged 18 to 59 years at base-
line. Exclusion criteria were a history of vascular, 
malignant or other immunological disease and 
MRI-related contra-indications, such as claustro-
phobia and a previous allergic reaction to a gadolin-
ium-based contrast agent.
Thirty patients and ten healthy controls were selected 
for this project. Subjects were randomly selected per 
site, for the patients based on availability of com-
pleted follow-up visits.
Neurological examination
At baseline, a medical history was taken and the 
Expanded Disability Status Scale (EDSS) was 
assessed by a trained physician. At follow-up visits, 
possible new symptoms leading to diagnosis of clini-
cally definite MS were registered and the EDSS 
assessment was repeated.
MRI acquisition
All patients received baseline MRI scans of the brain 
and spinal cord at both 1.5 and 3 T separated by 24–
72 hours (see Figure 1 for the illustration of the scan-
ning protocol and study design). For both magnetic 
field strengths, a multisequence scanner optimized 
acquisition protocol was used (detailed information is 
given in Supplementary Table 1). In summary, brain 
imaging included isotropic three-dimensional (3D) 
T1 and 3D fluid-attenuated inversion recovery 
(FLAIR), as well as axial 3 mm two-dimensional (2D) 
T2, proton density (PD) and post-contrast T1 spin-
echo (SE) sequences. From the 3D sequences, 3 mm 
axial reconstructions were made following the same 
repositioning compared to the 2D sequences. Spinal 
cord imaging included post-contrast sagittal 3 mm T1 
SE and PD/T2. According to the MAGNIMS guide-
lines on MS diagnosis and monitoring, axial spinal 
cord imaging was not included due to the substantial 
increase in scan duration.
In healthy controls, the same protocol was used 
without the administration of intravenous contrast. 
For the patients’ follow-up, the brain MRI protocol 
was repeated without the administration of intrave-
nous contrast.
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Imaging analysis
All scans were centrally collected and checked for 
completeness. The scans were rated independently 
by eight raters during a central reading session: four 
experienced raters (C.L., neuroradiologist for 8 years; 
A.R., neuroradiologist for 26 years; M.P.W., neurora-
diologist for 9 years; F.B., neuroradiologist for 
19 years) and four MS researchers or radiology resi-
dents considered as less-experienced raters (I.D.K., 
S.R., S.C., R.C.). For this central reading, the full 
scan protocol, as described in Figure 1, was availa-
ble. For each subject, the 1.5 and 3 T scans were pre-
sented separately with approximately a 20-hour time 
interval. The order of presentation was randomized 
between sessions, but the same for all the eight raters. 
Localization of symptoms at onset was presented for 
each patient, as per McDonald 2010 criteria sympto-
matic brainstem or spinal cord lesions are excluded 
from demonstration of DIS.8  Besides location of 
onset, the raters were blinded for clinical information 
such as age, gender and centre.
For all baseline scans, the number of inflammatory 
lesions larger than 3 mm in size were scored and 
Figure 1. Study protocol.
DIR: double inversion recovery; EDSS: Expanded Disability Status Scale; FLAIR: fluid-attenuated inversion recovery; FU: follow-up; 
PD: proton density; SDMT: standard digit modalities test; SE: spin-echo; T: Tesla.
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categorized according to the anatomical region 
(periventricular, juxtacortical, infratentorial and 
spinal cord). In CIS patients but not in healthy con-
trol subjects (no contrast administered), the number 
of enhancing lesions per region was reported. 
Subsequently, the presence of DIS and DIT accord-
ing to the McDonald 2010 criteria was determined. 
For follow-up scans, new lesions per region were 
scored and again fulfilment of the criteria for DIS 
and DIT was determined.
Statistical analysis
The difference in lesion detection between 1.5 and 3 T 
was tested using generalized estimating equations 
(GEEs) with a logit link function and an exchangea-
ble correlation structure. Repeated measures for each 
subject were defined as the scores of the different 
observers.
Inter-rater agreement on number of lesions detected 
per region was calculated with Conger’s kappa. 
Agreement on involvement per anatomical region, 
independent of the number of lesions scored in 
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that region, was calculated with Cohen’s kappa. This 
statistical analysis was also used to determine agree-
ment on the fulfilment of the criteria for DIS, DIT 
and MS. Values of 0.41 to 0.60 were considered as 
moderate agreement, 0.61 to 0.80 as substantial 
agreement and >0.81 as good agreement.17 
Calculations were performed using SPSS 22.0 
(Windows) and ‘R’ version 3.1.1.
Results
Patient characteristics
Detailed demographic information of the study sub-
jects is given in Table 1. The mean age for patients 
was 34.5 ± 7.0 years, 64% was female. The median 
EDSS at baseline was 2.0 (range 0–6). Most CIS 
patients presented with an optic neuritis (n = 12) or 
spinal cord syndrome (n = 11). Patients were scanned 
with a median of 90 days (interquartile range 
(IQR) = 29–123) after onset of the symptoms.
In healthy controls, the mean age was 38.7 ± 9.3 years, 
80% were female.
Lesion detection and diagnosis
In healthy controls, no spinal cord lesions were 
scored. The mean total number of brain lesions 
scored per rater per subject was 0.38 at 3 T (median 
0, IQR = 0–0.8) and 0.16 at 1.5 T (median 0, 
IQR = 0–0) (p = 0.005). In the patient group, the 
mean overall number of lesions at baseline was 
4.40 at 3 T (median 3, IQR = 1–7) and 4.14 at 1.5 T 
(median 3, IQR = 1–6) (p = 0.732), see Figure 2. 
Only very few enhancing juxtacortical and 
infratentorial lesions at baseline and new infraten-
torial lesions at follow-up were identified leading 
to the exclusion of these regions at these time 
points from further analyses.
The mean number of cases per rater diagnosed as MS 
based on radiological criteria was at baseline 1.63 at 
1.5 T (median 2, IQR = 1–2) and 2.25 at 3 T (median 2, 
IQR = 2–2), and at follow-up 4.63 at 1.5 T (median 5, 
IQR = 3.25–5.75) and 6.38 at 3 T (median 6, IQR = 6–
6). Full statistical analysis will be presented based on 
a consensus score after completion of our ongoing 
cohort study.
Inter-rater agreement on lesion detection
Inter-rater agreement on involvement per anatomical 
region for all the raters was moderate to good on both 
1.5 and 3 T, with kappa scores (κ) varying from 0.49 
to 0.84, see Figure 3. The agreement was highest for 
baseline infratentorial lesions (3 T: κ 0.84, 1.5 T: κ 
0.76) and lowest for baseline juxtacortical lesions 
(3 T: κ 0.53, 1.5 T: κ 0.49). Agreement on presence of 
spinal cord lesions was lower at 1.5 T compared to 3 T 
(3 T: κ 0.76, 1.5 T: κ 0.66). Agreement on enhancing 
lesions was substantial for periventricular lesions 
(3 T: κ 0.70, 1.5 T: κ 0.80) and moderate for spinal 
cord lesions (3 T: κ 0.57, 1.5 T: κ 0.59). Overall, agree-
ment on involvement of regions was higher at base-
line compared to follow-up.
As can be expected, inter-rater agreement dropped for 
the category ‘exact number of lesions scored per 
region’, see Figure 3. Agreement on enhancing lesions 
was not affected, as there was no more than one 
enhancing lesion in any anatomical region.
When looking at the kappa scores for involvement per 
anatomical region for the groups by experience, 
agreement on involvement per anatomical region was 
overall higher at 3 T for the experienced raters and 
overall higher at 1.5 T for the less-experienced raters, 
see Figure 4.
Inter-rater agreement on diagnosis
In CIS patients, the inter-rater agreement for DIS, DIT 
and diagnosis of MS at baseline was also moderate to 
good, with κ scores varying from 0.51 to 1.00, see 
Figure 5. The remarkable κ of 1.00 for DIT at 1.5 T at 
baseline for both experienced and less-experienced 
raters is due to full agreement on non-symptomatic 
Table 1. Demographics of clinically isolated syndrome 
patients and healthy controls.
Characteristics Patients 
(n = 30)
Controls 
(n = 10)
Age, mean ± SD (years) 34.5 ± 7.0 38.7 ± 9.3
Gender, male/female (n) 11/19 2/8
EDSS, median and range 2.0 (0–6)  
Location presenting 
symptoms (n):
 
 Optic nerve 12  
 Cerebral hemisphere 3  
 Infratentorial 4
 Spinal cord 11  
EDSS: Expanded Disability Status Scale; SD: standard 
deviation.
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enhancing lesions, and therefore DIT, in two patients. 
At 3 T part of the raters identified a non-symptomatic 
enhancing lesion in another six patients, leading to a 
drop in inter-rater agreement on DIT and the diagnosis 
of MS at 3 T.
At follow-up, 3 T slightly improved the inter-rater 
agreement for the experienced raters on DIS, DIT and 
MS, while the agreement between less-experienced 
raters slightly decreased on all criteria. Overall, the 
inter-rater agreement on the diagnosis of MS at follow-
up was substantial (κ 0.61–0.80) at both field strengths
Discussion
The McDonald criteria for the diagnosis of MS do not 
define important MRI acquisition parameters such as 
field strength.8 However, recent MAGNIMS guide-
lines recommend the use of 3 T brain MRI based on an 
improved signal-to-noise ratio resulting in higher 
lesion detection.1,2 Nonetheless, to date the extent of 
and the clinical relevance of a higher detection rate 
using higher magnetic field strength with respect to 
diagnostic and prognostic purposes remains unclear. 
This multicentre, multi-vendor and multi-rater study 
provides important information on the lesion detection 
rates and interobserver variation with respect to MS 
lesion detection for diagnostic purposes in patients pre-
senting with CIS suggestive of MS. Overall, inter-rater 
agreement on involvement per anatomical region was 
moderate to good, which was not substantially influ-
enced by field strength. With respect to the lesion loca-
tion, the agreement was the lowest for juxtacortical 
lesions at baseline. When comparing this to the 
Figure 2. 1.5 and 3 T MRI scans of two CIS patients. 1. 3DFLAIR brain scans of one CIS patient presenting with optic 
neuritis: (a) baseline scan on 3 T with no brain lesions, (b) follow-up scan on 3 T showing two new T2 lesions in the 
corpus callosum, (c) follow-up scan on 1.5 T on which only one of the new lesion can be identified. 2. Baseline (a) 3 and 
(b) 1.5 T 3DFLAIR brain scans of one CIS patient presenting with a spinal cord syndrome. All raters identified additional 
periventricular and juxtacortical lesions on 3 T MRI leading to dissemination in space, while only three experienced raters 
on 1.5 T.
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agreement on the exact number of lesions per region, 
the largest decrease in agreement was understandably 
in the periventricular region, as this is the region where 
most lesions were identified.
In contrast to a previous single-centre and single-
vendor study,15 we used 3D brain imaging with 
3-mm-thick axial reconstructions on both field 
strengths. Moreover, we also studied spinal cord 
imaging at both field strengths. Previous studies 
have shown that the identification of a spinal cord 
lesion does not only facilitate the fulfilment of the 
MRI criteria for diagnosis of MS, but is also predic-
tive for conversion to clinically definite MS in CIS 
patients.18,19 However, spinal cord MRI is challeng-
ing – especially at 3 T – due to various possible arte-
facts due to patient motion, swallowing, respiration 
and pulsation of the cerebrospinal fluid and blood 
vessels.20 In addition, it has not conclusively been 
demonstrated that 3 T leads to higher lesion detec-
tion levels compared to lower field strength.21 
Contrary to this, agreement on spinal cord lesions 
was highest at 3 T for both the experienced and less-
experienced raters.
When demonstrating the effect of the experience of 
the raters on the variability of lesion detection, 
overall the inter-rater agreement for the less-experi-
enced raters is higher for the 1.5 T scans, while the 
more experienced raters agree more at 3 T. This 
Figure 3. Agreement on lesions per anatomical region per field strength. Agreement between the eight raters on the 
involvement of an anatomical region, calculated with Cohen’s kappa scores, and on the exact number of lesions per 
anatomical regions, calculated with weighted Conger’s kappa scores. The horizontal lines indicate the cut-off values of 
0.41 for moderate agreement, 0.61 for substantial agreement and 0.81 for good agreement.
BL: baseline; E: enhancement; FU: follow-up; IT: infratentorial; JC: juxtacortical; PV: periventricular; SC: spinal cord.
Figure 4. Effect of experience on agreement on 
involvement per anatomical region per field strength. 
Calculated by subtracting Cohen’s kappa for 3 T by 
Cohen’s kappa for 1.5 T.
BL: baseline; E: enhancement; FU: follow-up; IT: infratentorial; 
JC: Juxtacortical; PV: periventricular; SC: spinal cord; T: Tesla.
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could be explained by an effect of training. Most 
probably, a correct interpretation of high field 
strength MRI requires more experience as smaller 
details become visible, including more incidental 
lesions in healthy controls.
Even though all eight raters were well familiar with 
the McDonald 2010 criteria, applying these criteria 
consistently to all the scans appeared to be more 
challenging than anticipated. A good working 
knowledge of these complex criteria was not with-
out doubt even for the experienced neuroradiolo-
gists. The difficulty of applying the diagnostic 
criteria for MS has previously also been demon-
strated when using the McDonald 2001 criteria.22 
For the 2010 revision of the diagnostic criteria, 
most questions arose on how to exclude the sympto-
matic brainstem and spinal cord lesions in the crite-
ria for DIS. In the current criteria, symptomatic 
lesions localized in the brainstem or spinal cord are 
to be excluded from lesion count. However, it is 
unclear as to whether only the one symptomatic 
lesion or all the lesions in the symptomatic area 
should be excluded when scoring DIS. Moreover, 
it can be quite difficult, if not impossible, to 
identify the particular lesion causing the clinical 
symptoms. These doubts ask for a simplification of 
the McDonald 2010 criteria, as recently proposed 
by the MAGNIMS study group.23 This is supported 
by recent studies indicating that including the symp-
tomatic lesion in the criteria for DIS, does not lead 
to a decrease in specificity and even increases the 
sensitivity of these diagnostic criteria.24,25
As a future perspective, the introduction of ultra-
high-field MRI creates new possibilities and chal-
lenges. Given the strong effect of tissue relaxation 
times, in particular on clinically recommended 
sequences (such as FLAIR, conventional T2 and 
optionally double inversion recovery), and the dif-
ferent appearances of cortical grey matter and white 
matter structures, the reading of 7 T images in the 
context of MS is likely to be even more challeng-
ing.26–32 7 T is now exclusively used in research and 
its future role in clinical practice remains uncertain. 
Possibly, the effect of training will be even stronger 
for ultra-high-field MRI.
In conclusion, this study demonstrates a moderate to 
good interobserver agreement on lesion detection, 
DIS and DIT, which was not substantially influenced 
by field strength. Furthermore, interobserver agree-
ment at 3 T was lower for less-experienced raters 
compared to experienced raters, indicating correct 
interpretation of high field strength MRI may require 
more training.
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